This document discusses criticisms of the DSM (Diagnostic and Statistical Manual of Mental Disorders) and the influence of the pharmaceutical industry on psychiatric diagnosis. It notes that many DSM panel members have financial ties to drug companies and that the DSM lacks transparency around these conflicts of interest. Several new diagnoses are criticized for medicalizing normal behaviors and expanding markets for drug companies. The reliability and validity of psychiatric diagnosis is questioned.